



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Amphiregulin as a driver of tissue fibrosis

Citation for published version:

Zaiss, D 2019, 'Amphiregulin as a driver of tissue fibrosis', *American Journal of Transplantation*.
<https://doi.org/10.1111/ajt.15743>

Digital Object Identifier (DOI):

[10.1111/ajt.15743](https://doi.org/10.1111/ajt.15743)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

American Journal of Transplantation

Publisher Rights Statement:

This is the peer reviewed version of the following article: Zaiss, D.M.W. (2020), Amphiregulin as a driver of tissue fibrosis. *Am J Transplant*. doi:10.1111/ajt.15743, which has been published in final form at <https://doi.org/10.1111/ajt.15743>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Amphiregulin as a driver of tissue fibrosis.

Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3FL, UK.

Correspondence should be addressed to Dietmar.Zaiss@ed.ac.uk

Most deaths in Western countries can currently be associated with fibrotic diseases. During fibrosis excessive amounts of extra-cellular matrix components, such as collagen, are deposited in tissues, which can lead to tissue stiffness and organ failure. The underlying mechanisms leading to tissue fibrosis remain poorly understood and, consequently, our capacities to treat fibrotic diseases remain limited. Currently approved drugs only delay the progression of fibrosis and are often associated with severe side-effects, which limit their clinical application. Thus, a better understanding of the ontology of fibrotic diseases and the development of more specific and more efficient drugs for the treatment of tissue fibrosis is an urgent clinical need.

Myofibroblasts are the major producers of extra-cellular matrix components and an expansion of myofibroblasts is observed during fibrosis. In mice, it is well established that blood vessel associated pericytes are the major source of myofibroblasts in fibrotic tissues¹. In particular, the local activation of the Transforming Growth Factor beta (TGF β) induces the differentiation of pericytes into myofibroblasts during the development of tissue fibrosis¹. The Epidermal Growth Factor (EGF) like growth factor Amphiregulin has recently been identified as being a critical factor that induces this local activation of TGF β on pericytes and thus their differentiation into myofibroblasts². Amphiregulin is a cytokine, involved in immunity against helminth infection, in immune regulation and in wound repair³. In accordance with the finding that Amphiregulin is an important driver for myofibroblast differentiation under inflammatory conditions, it has also been shown in various different model systems that Amphiregulin deficient mice are resistant to the development of tissue fibrosis⁴, while the injection of recombinant Amphiregulin into mice can induce fibrosis. However, these different mouse models are rather short-term models, while the ontology of human fibrotic diseases, based on chronic, local inflammation can stretch over several years. Furthermore, in human fibrotic diseases an Epithelial-Mesenchymal-Transition (EMT) seems to contribute to the expansion of myofibroblasts. Also EMT is a TGF β -driven process; nonetheless, these differences between humans and mouse models raised the question whether the underlying mechanisms for the development of tissue fibrosis can be translated into a human setting. In particular, whether Amphiregulin is also a driver of tissue fibrosis in humans.

In this regard, a recent publication by Todd et al. constitutes a major step forward⁵. The authors studied chronic lung allograft dysfunction (CLAD), a chronic inflammatory disease in lung transplant patients, which is characterized by excessive matrix deposition, leading to loss of lung function. They followed two cohorts of lung-transplant patients, who either developed CLAD or not. They found that the expression of Amphiregulin in the lungs of patients with CLAD is significantly higher than in those without CLAD. Critically, the authors also followed individual patients in a longitudinal study and found that increases in Amphiregulin expression in the lungs of patients directly correlated with the development of CLAD. Given the findings in mouse models, these data derived from these patient cohorts strongly suggest that also in CLAD patients Amphiregulin is a major driver of tissue fibrosis.

The finding that an EGF-like growth factor could contribute to tissue fibrosis may appear counter-intuitive at first, as a substantial fraction of cancer patients being treated with EGFR inhibitors develop lung fibrosis. But not only the low-affinity EGFR ligand Amphiregulin plays a critical role in the development of tissue fibrosis, but also the high-affinity ligand heparin-binding EGF-like growth factor (HB-EGF). The EGFR shows a so-called "agonistic bias",

which means that ligands with different affinities induce the activation of different downstream signalling pathways (Figure 1). Consequently, the low affinity-ligand Amphiregulin induces the activation of TGF β (Minutti), while the high-affinity ligand HB-EGF activates the intracellular inhibitor of TGF β -signalling TIGIF; in this way, preventing the differentiation of pericytes into myofibroblasts⁶. As a consequence, *Hbegf*^{-/-} mice develop more severe forms of tissue fibrosis⁶. The application of EGFR inhibitors in patients may thus block this HB-EGF-mediated physiological counterbalance to TGF β signalling and may thereby allow for the progression of an underlying form of tissue fibrosis in EGFR inhibitor treated cancer patients.

Thus, taken together, the publication by Todd et al.⁵ suggests a novel more refined approach for the treatment of tissue fibrosis, by targeting specifically Amphiregulin function. Furthermore, treating patients with lung transplants with such drugs could be an attractive first target group, as the development of CLAD is a rather frequent and predictable event, which could precisely be measured during clinical trials. Success of such drugs, such as for instance an Amphiregulin-neutralizing antibody, could then open the opportunity of applying such a drug to other fibrotic diseases and thus creating hope for resolving a major unmet clinical need.

Cited Literature:

[1] Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, Pellicoro A, Raschperger E, Betsholtz C, Ruminiski PG, Griggs DW, Prinsen MJ, Maher JJ, Iredale JP, Lacy-Hulbert A, Adams RH, Sheppard D: Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. *Nature medicine* 2013, 19:1617-24.

[2] Minutti CM, Modak RV, Macdonald F, Li F, Smyth DJ, Dorward DA, Blair N, Husovsky C, Muir A, Giampazolias E, Dobie R, Maizels RM, Kendall TJ, Griggs DW, Kopf M, Henderson NC, Zaiss DM: A Macrophage-Pericyte Axis Directs Tissue Restoration via Amphiregulin-Induced Transforming Growth Factor Beta Activation. *Immunity* 2019, 50:645-54 e6.

[3] Zaiss DM, Gause WC, Osborne LC, Artis D: Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. *Immunity* 2015, 42:216-26.

[4] Perugorria MJ, Latasa MU, Nicou A, Cartagena-Lirola H, Castillo J, Goni S, Vespasiani-Gentilucci U, Zagami MG, Lotersztajn S, Prieto J, Berasain C, Avila MA: The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. *Hepatology* 2008, 48:1251-61.

[5] Todd JL, Kelly FL, Nagler A, Banner K, Pavlisko EN, Belperio JA, Brass D, Weigt SS, Palmer SM: Amphiregulin contributes to airway remodeling in chronic allograft dysfunction after lung transplantation. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons* in press.

[6] Takemura T, Yoshida Y, Kiso S, Kizu T, Furuta K, Ezaki H, Hamano M, Egawa M, Chatani N, Kamada Y, Imai Y, Higashiyama S, Iwamoto R, Mekada E, Takehara T: Conditional loss of heparin-binding EGF-like growth factor results in enhanced liver fibrosis after bile duct ligation in mice. *Biochemical and biophysical research communications* 2013, 437:185-91.




Figure 1: The differential expression of two antagonistic EGF-like growth factors determines the functionality of local TGFβ.

The low affinity EGFR ligand Amphiregulin induces a sustained activation of PLCγ signalling. Such signalling induces the “inside-out” activation of integrin-α_v and thus the local, integrin-mediated release of bio-active TGFβ. In contrast, the high-affinity EGFR ligand HB-EGF induces the activation of the MAPK signalling pathway. The pronounced ERK activation induces the accumulation of TGIF, an intracellular repressors of TGFβ signalling. (HB-EGF induced EGFR signalling is depicted in green, while Amphiregulin induced EGFR signalling is depicted in red. TGFβ signalling is depicted in blue.)